In this study, to determine if DPP inhibition can enhance the efficacy of PD-1/PD-L1 blockade, the therapeutic effect of an anti-PD-1 antibody combined with PT-100 was investigated in the Lewis lung cancer model. Here, PDCD1 is linked to lung carcinoma.